Another UFC fighter is in hot water with USADA, this time coming off his promotional debut.
UFC Light Heavyweight Michal Oleksiejczuk, who last appeared at UFC 219 in December, has been hit with a potential anti-doping violation. The UFC announced late Thursday that the Polish fighter, who picked up a unanimous decision win over Khalil Rountree at the event, had failed an in-competition drug test.
Oleksiejczuk (13-2), made his promotional debut at UFC 219. Prior to that, he’d competed in Poland under the FEN (Fight Exclusive Night) and TFL (Thunderstrike Fight League) banners. Oleksiejczuk has won his last ten bouts, though should the initial failed test here be upheld, it’s likely he’ll see his win against Roundtree overturned.
The UFC’s full statement Thursday reads as follows:
The UFC organization was notified today that the U.S. Anti-Doping Agency (USADA) informed Michal Oleksiejczuk of a potential Anti-Doping Policy violation stemming from an in-competition sample collected in conjunction with his recent bout against Khalil Roundtree at UFC 219 in Las Vegas, Nevada on December 30, 2017.
USADA, the independent administrator of the UFC Anti-Doping Policy, will handle the results management and appropriate adjudication of this case involving Oleksiejczuk, as it relates to the UFC Anti-Doping Policy and future UFC participation. Because the Nevada Athletic Commission was the regulatory body overseeing the fight in Las Vegas and has licensing jurisdiction over Oleksiejczuk, USADA will work to ensure that the Nevada Athletic Commission has the necessary information to determine its proper judgment of Oleksiejczuk’s potential anti-doping violation. Additional information will be provided at the appropriate time as the process moves forward.
As is standard procedure, neither the UFC nor USADA announced the name of the substance the fighter tested positive for.